The anorectic effect of FG 7142, a partial inverse agonist at benzodiazepine recognition sites, is reversed by CGS 8216 and clonazepam but not food deprivation

Palatability-dependent appetite and benzodiazepines: new directions from the pharmacology of GABA(A) receptor subtypes

This paper updates an early review on benzodiazepine-enhanced food intake, published in the first issue of Appetite, and describes the considerable advances since then in the pharmacology of benzodiazepines, their sites and mechanisms of action, and in understanding the psychological processes leading to the increase in food consumption. A great diversity of benzodiazepine receptor ligands have been developed, many of which affect food intake. Agonists can be divided into full agonists (which produce the full spectrum of benzodiazepine effects) and partial agonists (which are more selective in their effects). In addition, inverse agonists have been identified, with high affinity for benzodiazepine receptors but having negative efficacy: these drugs exhibit anorectic properties. Benzodiazepine receptors are part of GABA(A) receptor complexes, and ligands thereby modulate inhibitory neurotransmission in the brain. Molecular approaches have identified a palette of receptor subunits from which GABA(A) receptors are assembled. In all likelihood, benzodiazepine-induced hyperphagia is mediated by the alpha2/alpha3 subtype not the alpha1 subtype. Novel alpha2/alpha3 selective compounds will test this hypothesis. A probable site of action in the caudal brainstem for benzodiazepines is the parabrachial nucleus. Behavioural evidence strongly indicates that a primary action of benzodiazepines is to enhance the positive hedonic evaluation (palatability) of tastes and foodstuffs. This generates the increased food intake and instrumental responding for food rewards. Therapeutic applications may derive from the actions of benzodiazepine agonists and inverse agonists on food procurement and ingestion.

Behavioral effects of betacarbolines in pigs:. anxiety or aversion?

Betacarbolines are often considered to be anxiogenic and may, therefore, have similar behavioral effects to those of corticotrophin releasing hormone (CRH); however, their actions have been little studied in pigs. This investigation was concerned with the effects of ethyl-beta-carboline-3-carboxylate (BCCE) and noreleagnine (NOR) on operant feeding, cortisol release, and overt behavior in swine, all of which are known to be affected by CRH in this species. Three experiments are described in which BCCE or NOR were given intravenously to prepubertal boars (n = 7). In Experiment 1, 400 microg/kg, but not 100 or 200 microg/kg, BCCE produced a rapid inhibition of ingestive activity whereas NOR (100, 200, or 400 microg/kg) was without effect. In Experiment 2, both BCCE and NOR increased plasma cortisol, but not growth hormone, concentrations. In Experiment 3, a high dose of BCCE (2 mg/kg) produced transient arousal and a sustained increase in respiration rate and plasma cortisol. These results indicate that although the responses of pigs to BCCE and CRH are similar in some respects, there are also marked behavioral differences. The possibility that BCCE has aversive rather than anxiogenic actions in this species is discussed.

Benzodiazepine-induced hyperphagia: development and assessment of a 3D pharmacophore by computational methods

Benzodiazepine receptor (BDZR) ligands are structurally diverse compounds that bind to specific binding sites on GABA(A) receptors and allosterically modulate the effect of GABA on chloride ion flux. The binding of BDZR ligands to this receptor system results in activity at multiple behavioral endpoints, including anxiolytic, sedative, anticonvulsant, and hyperphagic effects. In the work presented here, a computational procedure developed in our laboratory has been used to obtain a 3D pharmacophore for ligand recognition of the GABA(A)/BDZRs initiating the hyperphagic response. To accomplish this goal, 17 structurally diverse compounds, previously assessed in our laboratory for activity at the hyperphagic endpoint, were used. The result is a four-component 3D pharmacophore. It consists of two proton acceptor atoms, the centroid of an aromatic ring and the centroid of a hydrophobic moiety in a common geometric arrangement in all compounds with activity at this endpoint. This 3D pharmacophore was then assessed and successfully validated using three different tests. First, two BDZR ligands, which were included as negative controls in the set of seventeen compounds used for the pharmacophore development, did not fit the pharmacophore. Second, some benzodiazepine ligands known to have activity at the hyperphagia endpoint, but not included in the pharmacophore development, were used as positive controls and were found to fit the pharmacophore. Finally, using the 3D pharmacophore developed in the present work to search 3D databases, over 50 classical benzodiazepines were found. Among them, were benzodiazepine ligands known to have an effect at the hyperphagic endpoint. In addition, the novel compounds also found in this search are promising therapeutic agents that could beneficially affect feeding behavior.

Evaluation of exposure level of N-methyl-beta-carboline-3-carboxamide (FG 7142), an anxiogenic agent in humans

beta-Carboline-3-carboxylic acid methylamide (FG 7142), an anxiogenic agent, has been detected in human urine. The urinary excretion level of FG 7142 in non-smokers was found to be 0.503 +/- 0.25 ng per day (mean +/- S.D., n=10), while that in smokers was found to be 2.418 +/- 0.384 ng per day (n=10). This suggests that humans are exposed to FG 7142 and that smokers are exposed to higher levels of FG 7142 than non-smokers. Considering the previous findings that FG 7142 is present in cigarette smoke, indoor and outdoor air and smoke condensate of tree leaves, humans may be exposed to FG 7142 via the airways and lungs, although we cannot exclude the possibility of exposure via foodstuffs. Results of animal experiments suggest that FG 7142 which enters the bloodstream is excreted into the urine via the kidneys within 24 h in an unchanged form. Therefore, monitoring the level of FG 7142 in urine may be useful for monitoring the exposure level of FG 7142.

Benzodiazepines and palatability: taste reactivity in normal ingestion

The taste reactivity (TR) test was devised as a method to obtain behavioural data in response to gustatory stimuli in neurologically impaired rats, incapable of voluntary feeding. Sapid solutions were infused through surgically implanted intraoral cannulae. Facial and motor responses corresponded well to known hedonic and aversive properties of tastes (e.g., sweet, bitter). TR testing has since proved effective as an adjunct to intake-based methods, in the psychopharmacology of ingestion in the normal rat. We developed a nonsurgical modification of the TR test, in which intact rats sampled stimuli voluntarily. The benzodiazepine receptor agonist midazolam (3.0 mg/kg, IP) was administered to rats first trained to consume a sweet 3% sucrose solution, and later tested with access to a bitter 0.01% quinine solution. Response were videotaped, and TR measures were scored during periods of noningestion using a frame-by-frame playback. Treatment increased ingestion and facilitated ingestive responses in accordance with published data for cannulated rats. Results support a two-component view of response palatability, in which treatment alters feeding motivation, increasing positive palatability and facilitating ingestion of both palatable and unpalatable stimuli.

Food palatability and hunger modulated effects of CGS 9896 and CGS 8216 on food intake

The effect of food palatability and duration of food deprivation on the modulation of food intake by two benzodiazepine receptor (BDZR) ligands, CGS 9896 and CGS 8216, were investigated. Three diets differing in palatability (high, medium, or standard) and three different periods of food deprivation (0, 16, or 24 h) were used in all combinations to compare the effect of these variations on the observed modulation of food consumption by both BDZR ligands. Increasing diet palatability and/or food deprivation increased the baseline food consumption and reduced the sensitivity of the test to the detection of the hyperphagic effect of CGS 9896 but increased the sensitivity to detect the anorexic effect of CGS 8216. Only for the intermediate conditions of food deprivation (16 h) and for a standard or medium palatable diet were both significant hyperphagic effect of CGS 9896 and anorexic effect of CGS 8216 detected. Neither increased palatability nor hunger enhanced the modulation of feeding, indicating that neither "taste preference" nor "hunger" is the key factor in the mechanism of BDZR ligand-induced feeding response.

N-Methyl-beta-carboline-3-carboxamide (FG 7142): An anxiogenic agent in cigarette smoke condensate and its mechanism of formation

beta-Carboline-3-carboxylic acid methylamide (FG 7142), an anxiogenic agent has been found in cigarette smoke condensate, but not in the cigarette itself. When a cigarette, except its filter portion, was immersed in 20 ml of potassium phosphate buffer, pH 7.4, then heated at 60 degrees C for 2 days with or without presence of methylamine, FG 7142 was detected only in the mixture containing methylamine. Furthermore, when the mixtures of beta-carboline derivatives and various amounts of methylamine hydrochloride were heated at 60 degrees C for 5 days, FG 7142 was formed only in the mixtures containing methylamine and 1-methyl-1,2,3,4-tetrahydro-beta-carboline-3-caroxylic acid (MTCA) or 1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid (TCCA). FG 7142 was also produced in the mixture of glucose, l-tryptophan and methylamine when heated at 200 degrees C in a dry condition. These observations suggest that FG 7142 is formed through the smoking process and that methylamine in cigarette smoke may play an important role in the formation of FG 7142.

N-Methyl-beta-carboline-3-carboxamide (FG 7142), an anxiogenic agent in airborne particles and cigarette smoke-polluted indoor air

beta-Carboline-3-carboxylic acid methylamide (FG 7142), an anxiogenic agent, has been measured in airborne particles, automobile-exhaust particles, incinerator ash, smoke condensate of tree leaves and cigarette-smoke-polluted indoor air by high-performance liquid chromatography. This compound has been detected in indoor as well as outdoor air. The source of this compound in indoor air was determined as cigarette smoke, identified from smoking machine studies. This anxiogenic agent was detected in smoke condensate of tree leaves and incinerator ash from garbage burning plants, but not in diesel-exhaust particles. Considering the present results, together with the previous finding that cigarette smoke contains this compound, FG 7142 is likely to be formed through combustion of plants. Our data also suggest that this compound may be widely distributed in the environment.

The beta-carboline abecarnil, a novel agonist at central benzodiazepine receptors, influences saccharin and salt taste preferences in the rat

Abecarnil is a recently described beta-carboline which acts at central benzodiazepine receptors (BZR) and has anxioselective/anticonvulsant properties. While it may be classified provisionally as a partial agonist at BZR, there is also evidence that its pharmacological profile may be due to a selective action at BZR subtypes. The general aim of the present series of experiments was to investigate the effects of abecarnil on ingestional behaviour in the rat. The results indicated that abecarnil (0.3-10 mg/kg, i.p.) selectively increased the intake of preferred 0.05% sodium saccharin and 0.9% sodium chloride solutions in two-choice tests using water-deprived rats. These results confirm and extend previous work with the potent BZR agonist clonazepam. Moreover, abecarnil significantly increased the ingestion of sweetened mash and 3% sucrose solution in nondeprived animals. In general, these results indicate that abecarnil is effective in increasing ingestional responses, a characteristic it shares with classical agonists like diazepam. The results could be accounted for in terms of a partial agonist profile for abecarnil, but do not rule out the possibility of selective actions at BZR subtypes.

Inverse agonist properties of the FG 7142 discriminative stimulus

A two-lever, food-motivated discrimination was established between the benzodiazepine receptor partial inverse agonist FG 7142 (5.0 mg/kg) and its vehicle. The FG 7142 discriminative stimulus was pharmacologically characterized by testing trained rats with a variety of benzodiazepine receptor ligands. Administration of the inverse agonist DMCM (0.15-0.30 mg/kg) dose-dependently mimicked the FG 7142 stimulus. In contrast, the benzodiazepine receptor agonist chlordiazepoxide, partial agonist ZK 91 296, mixed agonist/antagonist CGS 9896 and antagonist RO 15-1788 blocked the FG 7142 cue. These results indicate that the FG 7142 discriminative stimulus is based on its inverse agonist activity. The generalization of FG 7142 to the anxiogenic/convulsant compound pentylenetetrazole (PTZ), but not to the anorectic agent norfenfluramine, indicates that the anxiogenic properties of FG 7142, rather than its anorectic actions, may underlie the FG 7142 discriminative stimulus.

Effects of 8-OH-DPAT, buspirone and ICS 205-930 on feeding in a novel environment: comparisons with chlordiazepoxide and FG 7142

Previously, the 5-hydroxytryptamine (5-HT)1A receptor agonists, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and buspirone and the 5-HT3 receptor antagonist ICS 205-930 have been shown to exert anxiolytic-like effects in several animal models. In the experiments reported here the effects of these compounds on feeding behaviour and food preference in a novel environment were examined, and compared with the effects of the anxiolytic drug chlordiazepoxide and the anxiogenic compound FG 7142. Chlordiazepoxide significantly reduced the latency to begin eating and prolonged the total time spent eating; chlordiazepoxide also abolished food neophobia, by significantly increasing the time spent eating novel food items. In contrast, FG 7142 significantly increased eating latency and reduced eating duration. Both 8-OH-DPAT and buspirone significantly enhanced eating duration, but unlike chlordiazepoxide eating was directed only towards the familiar food. In addition buspirone, but not 8-OH-DPAT, reduced eating latency. ICS 205-930 significantly increased eating latency and reduced eating duration; however, these effects were observed only at the lowest dose tested. All of these behavioural effects were observed only when animals were unfamiliar with the testing situation, and cannot be accounted for in terms of changes in mechanisms controlling hunger. The behavioural paradigm used in these experiments may induce a competition between the drives to explore a novel environment and to eat. It is suggested that the tendency of buspirone and 8-OH-DPAT to suppress exploratory activity may thus result in enhanced feeding duration.(ABSTRACT TRUNCATED AT 250 WORDS)

Effects of the imidazobenzodiazepine Ro 15-4513 on saccharin choice and acceptance, and on food intake, in the rat

The general aim of the present series of experiments was to investigate the effects of the imidazobenzodiazepine, Ro 15-4513, on ingestional behavior in the rat. The more specific aims were to test its effects on preference for sweet taste, to determine if it acts as a benzodiazepine-receptor inverse agonist, and if it selectively reduces sweetness preference. The results indicated that Ro 15-4513 (1.0-10 mg/kg, i.p.) abolished the preference for a 0.05% sodium saccharin solution in a two-choice test. Water intake in the same test was unaffected. Second, at 10 mg/kg, it suppressed saccharin ingestion in an acceptance test; this effect was completely reversed by the selective benzodiazepine antagonist, Ro 15-1788 (20 mg/kg). Third, Ro 15-4513 (1.0-10 mg/kg) reduced palatable food consumption in non-deprived rats, an effect which was also antagonized by Ro 15-1788. The results are consistent the bidirectional modulation of ingestional responses to palatable taste stimuli as a consequence of drug actions at benzodiazepine receptors. Furthermore, they emphasize that any reduction in consummatory responses produced by Ro 15-4513 is likely to reflect inverse agonist characteristics, as distinct from any putative ethanol antagonist property.

Clonazepam selectively increases saccharin ingestion in a two-choice test

Twenty-two-hour water-deprived rats were trained with a choice between a sodium saccharin solution (0.01% or 0.05%) and water in a 30-min drinking test. The potent benzodiazepine agonist, clonazepam, produced highly significant dose-related (0.1-1.0 mg/kg, i.p.) increases in total fluid consumption. The most important finding was that clonazepam selectively enhanced ingestion of the preferred 0.05% solution, while producing no change in the consumption of water. It did not selectively affect ingestion of the marginally preferred 0.01% solution. These data can be linked to recent evidence that benzodiazepines facilitate positive ingestive reactions elicited by palatable tastes. Together, the evidence indicates that benzodiazepines can selectively affect consumption of preferred solutions through enhancement of positive reactions to palatable tastes. In contrast to the results with clonazepam, the novel compound zolpidem, which binds preferentially to cerebellar-type benzodiazepine sites, failed to affect fluid intake or sweet taste preference. This suggests that hippocampal-type, as distinct from cerebellar-type receptors, may be necessary in the mediation of effects of benzodiazepines on taste-palatability processing and ingestion.

Bi-directional changes in sham feeding in the rat produced by benzodiazepine receptor ligands

Both the real and sham intake of a 5% sucrose solution were increased by midazolam (3 mg/kg IP), a benzodiazepine agonist. In contrast, both the real and sham intakes of a 20% sucrose solution were reduced by Ro15-3505 (a benzodiazepine antagonist with weak inverse agonist properties) and by FG 7142 (a beta-carboline inverse agonist). These data demonstrate that drugs acting at benzodiazepine receptors can bi-directionally alter ingestional responses, probably by modulation of the oropharyngeal control of consumption.

Anxiogenic properties of beta-CCE and FG 7142: a review of promises and pitfalls

The behavioral effects of the benzodiazepine (BZP)-receptor partial inverse agonists, beta-CCE and FG 7142, are reviewed and the claim that these compounds possess "anxiogenic" properties is examined. Results obtained from human studies and global observations in animals, as well as those from experiments on aggression in animals or from studies of pentylenetetrazole discrimination cannot be considered conclusive. Contradictory findings have been obtained in studies using animal testing procedures derived from BZP-sensitive models of anxiety and in newer experimental situations and these are discussed from various theoretical perspectives: (1) the ability of the models to measure increased anxiety; (2) the possible ability of the drugs to reveal latent anxiety which generalizes from a punished to an otherwise non-fearful component of a testing procedure ("spreading anxiety"); (3) anxiety produced by a pro- or pre-convulsant state. Finally, several hypotheses are considered to account for the behavioral effects of beta-CCE and FG 7142 without assuming anxiogenic properties. These include the possible existence of different forms of anxiety, rate dependency, and drug-induced motivational changes. It is concluded that available data are insufficient to strongly support the notion that FG 7142 and beta-CCE are the anxiogenic drugs "par excellence" they are often claimed to be.

Bidirectional changes in the consumption of food produced by beta-carbolines

beta-Carboline derivatives provide examples of benzodiazepine receptor ligands which span the range: full agonist-partial agonist-antagonist-partial inverse agonist-full inverse agonist. Taken together, the effects of these compounds illustrate two important principles: firstly, the bidirectionality of effects which can be achieved using benzodiazepine receptor ligands; secondly, the selectivity of effects which are produced by partial agonists. Applied to the study of feeding processes, these principles imply that both hyperphagic and anorectic effects can be generated by actions of selected ligands at benzodiazepine receptors. Furthermore, they suggest that a hyperphagic effect may occur in the absence of side-effects (e.g., sedation, muscle-relaxation), which are characteristic of classical benzodiazepines. Experimental data in support of these predictions are presented. A microstructural approach to feeding behavior indicated that a benzodiazepine receptor agonist and an inverse agonist extend and abbreviate, respectively, the duration of individual bouts of eating. Preference for a saccharin solution was attenuated by the beta-carboline inverse agonist, FG 7142, but rejection of a quinine solution was not increased. Adrenalectomy had no effect on the anorectic effect of inverse agonists.

Partial agonists acting at benzodiazepine receptors can be differentiated in tests of ingestional behaviour

Several categories of compounds active at benzodiazepine receptors (BZR) in the brain have been distinguished: agonists, antagonists and the novel category of inverse agonist. In terms of their effects on ingestional responses (e.g., food, saline and water consumption), agonists increase levels of intake, inverse agonists reduce intake in some, if not all, tests, while antagonists block the effects of both agonists and inverse agonists. Attention is currently focussed upon a range of compounds which fall between full agonists and antagonists. These partial agonists are of particular interest since they act more selectively than full agonists, retaining effects in animal models of anxiolytic and anticonvulsant activity, for example, while largely lacking behaviourally-depressant effects. Recent data indicate that tests of ingestional behaviour distinguish between various BZR partial agonists. The benzodiazepines Ro23-0364, Ro16-6028 and Ro17-1812, as well as the beta-carboline ZK 91296, enhanced ingestional responses. The pyrazoloquinolines, CGS 9895 and CGS 9896, did not, but antagonized agonist-induced increases in ingestion.

Beta-carbolines characterized as benzodiazepine receptor agonists and inverse agonists produce bi-directional changes in palatable food consumption

Drugs which bind to specific benzodiazepine recognition sites fall into three categories: agonists, antagonists, and inverse agonists. A set of biochemical parameters is available which distinguishes between the three. In addition, actions of the drugs result in physiological and behavioural effects which are distinguishable. beta-Carboline derivatives provide a group of compounds which show high affinity for the benzodiazepine sites, and which contains examples belonging to each of the three categories. Evidence is reviewed which shows that beta-carboline benzodiazepine receptor agonists (ZK 93423, ZK 91296) produce increases in the consumption of a palatable diet by non-deprived rats, that beta-carboline inverse agonists (FG 7142, DMCM) produce an anorectic effect, and that the beta-carboline ZK 93426 acts as a benzodiazepine receptor antagonist. The results support the proposal of bi-directional control of feeding responses through the action of drugs at a common benzodiazepine receptor. Furthermore, benzodiazepine receptor inverse agonists provide a novel class of anorectic agents. Evidence is also reviewed which is suggestive of the modulation of food-related reward by drug actions at benzodiazepine receptors.

Midazolam-induced hyperphagia and FG 7142-induced anorexia: behavioural characteristics in the rat

Non-deprived male rats, familiarized with a highly palatable diet, were treated with 0.3-10.0 mg/kg of the imidazobenzodiazepine midazolam. The increases in consumption of the food observed at larger doses of midazolam were due to increases in the duration of feeding, but not in the rate of eating. These, in turn, were due to increases in the duration of eating bouts, but not in their frequency. The beta-carboline FG 7142, a partial benzodiazepine receptor inverse agonist, reduced the consumption of the diet when it was injected at 10.0 and 15.0 mg/kg (IP). The overall duration of feeding was not affected at these doses in the 30 min test, but rate of eating was reduced. However, during the first 5 min interval of the test, when feeding behaviour was most motivated, FG 7142 did significantly reduce the duration of feeding. The effect depended upon a reduction in the duration of eating bouts, but not upon any change in their frequency. Hence, midazolam and FG 7142 had opposite effects on the duration of bouts of feeding. Both midazolam and FG 7142 reduced the frequencies of concurrent grooming, locomotor activity, and rearing in the test of palatable food consumption. Possible explanations for these effects are briefly considered.

Hyperphagic and anorectic effects of beta-carbolines in a palatable food consumption test: comparisons with triazolam and quazepam

The triazolobenzodiazepine triazolam (0.1-1.0 mg/kg i.p.) and quazepam (0.3-30.0 mg/kg i.p.) were administered to non-food-deprived rats which had been partially-satiated on a palatable diet. In a subsequent 30 min feeding test, both compounds produced a significant increase in the level of food consumption. While triazolam had a dose-related effect and produced a 151.5% increase in the level of food intake, quazepam exerted only a partial effect, achieving a 73.9% increase in food intake at 3.0 mg/kg but no additional increase in food intake at higher doses. The two beta-carbolines, ZK 93423 (0.1-3.0 mg/kg i.p.) and ZK 91296 (1.0-30.0 mg/kg i.p.), a full agonist and a partial agonist at benzodiazepine receptors respectively, also produced significant increases in food consumption under the same experimental conditions. ZK 93423 had effects which were similar to those of triazolam, ZK 91296 had effects similar to quazepam. The beta-carboline benzodiazepine inverse agonist FG 7142 (10.0 mg/kg i.p.) had an anorectic effect in non-food-deprived rats given 30 min access to the highly palatable diet. This effect was reversed by the beta-carboline benzodiazepine receptor antagonist ZK 93426 in a dose-dependent manner. These results emphasize that within the series of beta-carboline ligands for benzodiazepine receptors, their characterization in terms of agonists, antagonists and inverse agonists has validity with respect to the behavioural response of palatable food consumption in non-food-deprived rats.

Bidirectional control of palatable food consumption through a common benzodiazepine receptor: theory and evidence

A classical approach to the control of food consumption has been to assume separate mechanisms for the arousal to eat, on the one hand, and the satiation of feeding responses, on the other. The present paper is concerned with a single, and a comparatively simple, neuronal mechanism which is endowed with properties to allow the complete determination of the level of feeding, from hyperphagia to anorexia. The model for the control of feeding, which is presented here, draws attention to the benzodiazepine receptor found distributed through the brain, and present in certain hypothalamic nuclei. Recent evidence which characterizes the receptor is reviewed, and the various categories of benzodiazepine receptor ligands are described. Pharmacological data, collected in a palatable food consumption model using non-food-deprived rats, demonstrate that benzodiazepine receptor agonists produce hyperphagia, benzodiazepine receptor inverse agonists produce anorexia, and benzodiazepine receptor antagonists block both effects. Hence, bidirectional control of food intake can be achieved through differential ligand action at a common set of receptors. Speculatively, these data can be extended, if it is assumed that two endogenous ligands exist in the brain which act like benzodiazepine agonist and inverse agonist, respectively. Evidence for the presence in hypothalamic nuclei of endogenous ligands of the latter kind is discussed. Benzodiazepine withdrawal-induced anorexia is also described, and is taken as evidence for the part played by feeding mechanisms in the development of benzodiazepine physical dependence.